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ABSTRACT 
 
Feline Pancreatic Lipase: Purification and Validation of a Clinically Significant 
Radioimmunoassay for the Diagnosis of Feline Pancreatitis.  (December 2003) 
Benjamin Gregg Wilson, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Jörg M. Steiner 
 
 
 
Serum lipase activity has traditionally been used for diagnosis of pancreatitis in 
human beings and dogs.  However, serum lipase activity is not specific for exocrine 
pancreatic function and many cell types other than pancreatic acinar cells also synthesize 
lipases.  Recently, an immunoassay for the measurement of canine pancreatic lipase 
immunoreactivity has been developed and validated.  This assay has shown to be 
specific for exocrine pancreatic function and sensitive for the diagnosis of canine 
pancreatitis.  The objectives of this project were to purify feline pancreatic lipase (fPL), 
have antibodies against fPL (anti-fPL antibodies) produced, and develop a 
radioimmunoassay (RIA) for the diagnosis of feline pancreatitis. 
Pancreatic lipase was purified from feline pancreatic tissue by delipidation, 
anion-exchange chromatography, size-exclusion chromatography, and cation-exchange 
chromatography.  Antiserum against fPL was raised in rabbits.  Tracer was produced by 
iodination (125I) of fPL using the chloramine T method.  An RIA was established and 
validated by determination of sensitivity, dilutional parallelism, spiking recovery, intra-
  
iv
assay variability, and inter-assay variability.  A control range for fPLI in cat serum was 
established from 30 clinically healthy cats using the central 95th percentile. 
The sensitivity of the fPLI assay was 1.2 μg/L.  Observed to expected ratios for 
serial dilutions ranged from 58.0 to 164.3% for 4 different serum samples at dilutions of 
1 in 2, 1 in 4, and 1 in 8.  Observed to expected ratios for spiking recovery ranged from 
76.0 to 156.5% for 4 different serum samples and 6 different spiking concentrations.  
Coefficients of variation for intra-assay variability for 4 different serum samples were 
10.1, 4.5, 2.2, and 3.9%.  Coefficients of variation for inter-assay variability for 4 
different serum samples were 24.4, 15.8, 16.6, and 21.3%.  The control range for serum 
fPLI concentration was established as 1.2 to 3.8 μg/L. 
All of the objectives outlined above were successfully met, leading to the 
development of an RIA for the measurement of fPLI in cat serum.  The RIA for fPLI 
described here is sufficiently accurate and precise, but has a limited linearity and 
reproducibility in the lower and higher end of the working range. 
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CHAPTER I 
INTRODUCTION 
 
LIPASES 
Lipases were first discovered in 1856 by Claude Bernard when he studied the 
role of the pancreas in fat digestion.1  Since then many different lipases have been 
identified in and isolated from bacteria, fungi, plants, and animals.2-7  Lipases are 
characterized as enzymes capable of hydrolyzing water-insoluble substrates, such as 
triglycerides, into more polar lipolysis products.1  It has been shown that lipases share a 
common amino acid sequence motif, G-X-S-X-G (glycine-variable-serine-variable-
glycine).  This amino acid sequence motif is also shared with esterases, some related 
proteins, and serine proteases.1,8,9  While being hydrophilic in serine proteases, this 
amino acid sequence has been shown to be hydrophobic in nature in lipases.  This 
indicates that the two sequences are phylogenetically unrelated.10  Lipases and serine 
proteases also share another common property found within the active site of these 
enzymes.11  They both contain three amino acids, serine, aspartic or glutamic acid, and 
histidine, commonly known as the catalytic triad.11  The amino acid sequence motif for 
the active site of human pancreatic lipase is Ser152, Asp176, and His263.11 
Many of the lipases that have been identified to date are phylogenetically related.  
The pancreatic lipase gene family is large and has been subdivided into nine subfamilies: 
__________________________ 
This thesis follows the style and format of the American Journal of Veterinary Research. 
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yolk proteins, lipoprotein lipase, hepatic lipase, classical pancreatic lipase, pancreatic 
lipase-related protein 1 (PLRP1), pancreatic lipase-related protein 2 (PLRP2), a group 
that contains a phosphatidylserine-specific phospholipase A1 from rat platelets and a 
protein expressed in human melanoma cell lines known as NMD, vespid phospholipases 
A1, and lastly endothelial lipase.1,12-15  This project will focus solely on the digestive 
lipase known as classical pancreatic lipase. 
Classical pancreatic lipase (also known as pancreatic lipase, PL) is a glycoprotein 
that has an estimated molecular mass of 50,000 Da in human beings.16  Classical 
pancreatic lipase is synthesized in the pancreas, more specifically by pancreatic acinar 
cells.  Pancreatic lipase is secreted as an active enzyme into the duct system of the 
exocrine pancreas from where it is transported into the duodenum.17  Although the 
activity of PL towards water-soluble substrates is low in solution, the enzyme’s activity 
is significantly increased at the interface between water and aggregated water-insoluble 
triglycerides.15  This characteristic of increased lipase activity at an oil-water interface is 
known as interfacial activation.15  Bile acids, even at physiological concentrations, have 
the ability to inhibit triglyceride hydrolysis by covering the oil-water interface. However, 
in the presence of colipase, which interacts with PL in a molecular ratio of 1:1 and also 
facilitates the adsorption of lipase at the bile acid covered interface, this inhibition is 
reversible.15,16  Many detergents also exhibit an inhibitory action on PL activity.18  The 
three-dimensional structure for many pancreatic lipases has previously been deduced, 
though the structure of human PL was the first described.19  From all species where the 
structure has been determined, PL is folded into two domains, with the N-terminal 
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domain being larger than the C-terminal domain.20  The smaller C-terminal domain plays 
a role in the binding of lipase to colipase and is very important for the interfacial binding 
of PL.20-26  The catalytic triad or active site is located within the larger N-terminal 
domain, which also contains a glycosylation and a potential heparin-binding site.20  In 
human beings, the PL active site contains the three essential amino acid residues Ser153, 
His264, and Asp177.27  A mutation of any of these essential amino acid residues will 
result in a protein that does not display lipolytic activity.27  However, a site-directed 
mutation of Asp177 to Glu177 leads to PL with lipolytic activity, but with an increased 
sensitivity to proteases.28 
Two major digestive lipases have been reported in most mammalian species, PL 
and preduodenal lipase.29  Pancreatic lipase has proven to be the most important lipase 
for digestion of dietary fats.30,31  This water-soluble digestive enzyme is capable of 
hydrolyzing apolar dietary triglycerides into more polar lipolysis products, like 
monoglycerides and free fatty acids, that can be absorbed by the intestinal mucosa.32  
Upon completion of a meal, when foodstuffs reach the small intestine, specific receptors 
are activated that lead to the release of cholecystokinin which in turn activates a cyclic 
AMP pathway that stimulates the secretion of PL from the pancreas into the small 
intestine.33,34  The activity of PL is limited to the small intestine due to the proteolysis by 
chymotrypsin.25,35  Acid denaturation can also play a role in the loss of lipolytic activity 
as the enzyme progresses through the gastrointestinal tract.36  The degradation and 
denaturation processes may be slowed by the presence of nutrients in the intestine.36 
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LIPASE ASSAYS 
A myriad of different methods to evaluate catalytic lipase activity have been 
developed.  One downside to having multiple methods for analysis is that the inter-assay 
variability between the assays of differing methods is large and a reference method has 
yet to be agreed upon.37  The substrate used in the catalytic lipase activity assays is yet 
another factor of variability between methods.  Many assays employ the use of oil based 
substrates such as olive oil or triolein suspensions while other assays depend on 
synthetic substrates.38  As mentioned previously, lipase shows its maximal hydrolytic 
activity at a water-oil interface, thus the use of a water-soluble synthetic substrate could 
prove to be problematic in that it may yield a lower reading of catalytic activity when in 
fact there may be large amounts of lipase present.38 
 
CLINICAL APPLICATION OF LIPASE ASSAYS 
The measurement of PL activity has been used as a tool for the diagnosis of 
exocrine pancreatic disorders in human beings for many years.39-41  However, enzymatic 
assays are not capable of distinguishing between lipase activity of different cellular 
origins and serum lipase activity does not exclusively originate from the pancreas.  This 
is supported by research that shows lipase activity in serum after a total pancreatectomy 
in dogs.42,43 
Research has shown that human beings with exocrine pancreatic insufficiency 
have a decreased serum lipase activity, while increased serum lipase activities have been 
observed in patients with acute pancreatitis.44-46  One study conducted in dogs without 
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any lesions of the exocrine pancreas as determined by light microscopy showed serum 
lipase activities that were significantly elevated.39  These dogs were diagnosed with renal 
diseases, hepatic lesions, and other lesions of the heart, gastrointestinal tract, and 
multiple other organs.39  Other factors that can lead to an increased serum lipase activity 
in dogs, although they are small increases, are heat stress and muscular exercise.47  Thus, 
increased serum lipase activity is not highly specific for pancreatitis.45,48   
Pancreatitis used to be diagnosed infrequently in cats.  However, recent studies 
have shown that pancreatitis occurs frequently in cats and have led to an increased level 
of suspicion by veterinary clinicians.49  However, definitive diagnosis of feline 
pancreatitis remains elusive.  Clinical signs in cats with pancreatitis are non-specific and 
key clinical signs seen in human beings and dogs with pancreatitis, such as vomiting and 
abdominal pain, are only reported infrequently in cats.50  Also, findings on blood work 
are non-specific and serum amylase and serum lipase activities are of no clinical value in 
the cat.  Abdominal radiography can show findings that are compatible with pancreatitis 
but do not allow for a definitive diagnosis.  When stringent criteria are applied 
abdominal ultrasound is highly specific for feline pancreatitis but its sensitivity is only 
11-35%.51  Measurement of serum feline trypsin-like immunoreactivity (fTLI) is also 
highly specific for pancreatitis but its sensitivity of 30-60% is also less than optimal.51-54  
Thus, a minimally-invasive diagnostic test that is both highly sensitive and specific for 
feline pancreatitis is needed. 
 
  
6 
OBJECTIVE 
The objective of this project was to evaluate the hypothesis that the measurement 
of serum feline pancreatic lipase immunoreactivity (fPLI) is useful for the diagnosis of 
exocrine pancreatic disorders in the cat.  To test this hypothesis, feline pancreatic lipase 
was purified from pancreatic tissue, then antiserum against this protein was raised, and 
finally a radioimmunoassay for the measurement of fPLI in serum was developed and 
validated.  To thoroughly analyze the hypothesis, a collection of serum samples from 
clinically healthy cats and cats with exocrine pancreatic disorders was compiled to 
compare serum fPLI concentrations between these two groups of cats. 
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CHAPTER II 
PURIFICATION OF FELINE PANCREATIC LIPASE* 
 
INTRODUCTION 
Classical pancreatic lipase (also known as pancreatic lipase, PL) is a glycoprotein 
that has an estimated molecular mass of 50,000 Da in human beings.16  Pancreatic lipase 
is synthesized in the pancreas, more specifically by pancreatic acinar cells.  Pancreatic 
lipase is secreted as an active enzyme into the duct system of the exocrine pancreas from 
where it is transported into the duodenum.17  Although the activity of PL towards water-
soluble substrates is low in solution, the enzyme's activity is increased at the interface 
between water and aggregated water-insoluble triglycerides.15  This characteristic of 
increased lipase activity at an oil-water interface is known as interfacial activation.15  
Bile acids, even at physiological concentrations, inhibit triglyceride hydrolysis by 
covering the oil-water interface. However, in the presence of colipase, which interacts 
with PL in a molecular ratio of 1:1 and also facilitates the binding of lipase at the bile 
acid covered interface, this inhibition is reversible.15,16  Colipase is a small protein that is 
also secreted by pancreatic acinar cells and has an approximate molecular mass of 10 
kDa.55-57  Many detergents also have an inhibitory action on PL activity.18  The three-
dimensional structure for many pancreatic lipases has previously been deduced, though 
__________________________ 
*Parts of this chapter are reprinted from Comparative Biochemistry and Physiology Part 
B, Vol. 134, Jörg M. Steiner, Benjamin G. Wilson, David A. Williams, Purification and 
partial characterization of feline classical pancreatic lipase, Pages 151-159, © 2002 with 
permission from Elsevier Science Inc.
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the structure of human PL was the first one described.19  All pancreatic lipases for which 
the structure has been determined have exhibited a structure folded into two domains, 
with the N-terminal domain being larger than the C-terminal domain.20  The smaller C-
terminal domain plays a role in the binding of lipase to colipase and is very important for 
the interfacial binding of PL.20-26  The catalytic triad or active site is located within the 
larger N-terminal domain which also contains a glycosylation and a potential heparin-
binding site.20  In human beings, the PL active site is comprised of the three essential 
amino acid residues Ser153, His264, and Asp177 which are also found in many other 
lipases as well as in serine proteases.27  If there is a  mutation of any of these essential 
amino acid residues the protein does not display lipolytic activity.27  However, if the 
protein undergoes a site-directed mutation of Asp177 to Glu177 lipolytic activity will be 
present at the expense of a heightened sensitivity to proteases.28 
The measurement of serum lipase activity has been used as a tool for the 
diagnosis of pancreatitis in human beings for many years.39-41  Most studies in human 
beings utilize the measurement of lipase activity rather than that of a mass concentration 
of PL present.  Catalytic assays may not be capable of distinguishing between lipase 
activity of different origins and lipase activity measured in serum does not exclusively 
originate from the pancreas.  This is supported by research in dogs that shows that 
significant lipase activity remains in serum after total pancreatectomy.42,43   
Recent studies have shown that pancreatitis occurs frequently in cats, which has 
led to an increased level of suspicion by veterinary clinicians.49  However, definitive 
diagnosis of feline pancreatitis remains elusive.  Clinical signs in cats with pancreatitis 
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are non-specific and key clinical signs seen in human beings and dogs with pancreatitis, 
such as vomiting and abdominal pain, are only reported infrequently in cats.50  Also, 
findings on blood work are non-specific and serum amylase and serum lipase activities 
are of no clinical value in the cat.  Abdominal radiography can show patterns that are 
compatible with pancreatitis but do not allow for a definitive diagnosis.  When stringent 
criteria are applied, abdominal ultrasound is highly specific for feline pancreatitis but its 
sensitivity is only 11-35%.51  Measurement of serum feline trypsin-like 
immunoreactivity (fTLI) is also highly specific for pancreatitis but its sensitivity of 30-
60% is also less than optimal.51-54  Thus, a minimally-invasive diagnostic test that is both 
highly sensitive and specific for feline pancreatitis is needed.  The purification of feline 
PL, as described in this section, is a prelude to the development, validation, and clinical 
evaluation of a radioimmunoassay for the measurement of feline pancreatic lipase 
immunoreactivity in serum from cats suspected of having exocrine pancreatic disorders. 
 
MATERIALS AND METHODS 
Materials -  All commonly used research materials and supplies were purchased 
from VWR Scientific, West Chester, PA.  Chemicals and reagents used were from 
Sigma Chemicals, St. Louis, MO.  The liquid chromatography system (Äkta® purifier) 
and all columns used for the purification of feline PL were purchased through 
Amersham Pharmacia Biotech, Piscataway, NJ.  For the measurement of lipolytic 
activity a pH stat titration system was purchased from Brinkmann Instruments, 
Westbury, NY.  The electrophoresis system used for SDS-PAGE was from Novex, San 
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Diego, CA.  A NuPAGE 10% Bis-Tris Novex high-performance, pre-cast gel (1.0 mm X 
10 well) from Invitrogen™ life technologies was used for estimation of molecular mass. 
Lipase assay -  Throughout the purification it was necessary to measure the 
amount of lipolytic activity present in each fraction collected.  Lipolytic activity was 
measured with a pH stat assay using tributyrin as the substrate in the presence of feline 
pancreatic colipase.  For this assay an acidic colipase preparation was prepared by 
dissolving 1 g of delipidated feline pancreatic extract in 50 ml of 20 mM Tris-HCl, 3.3 
mM CaCl2, 2 mM benzamidine, 5 mM 3-phenyl propionate, 1 mM 
phenylmethylsulfonyl fluoride (PMSF) added in isopropyl alcohol, pH 8.0 and mixed at 
4°C for 2 hours.  This mixture was then centrifuged at approximately 12,000 g and 4°C 
for 30 min and the precipitate was discarded.  The supernatant was analyzed for lipolytic 
activity and the pH was adjusted to pH 2.0 using 6 N HCl.  The solution was centrifuged 
again under the same conditions as above and lipolytic activity of the supernatant was 
measured once again and the solution was adjusted to a pH of 5.0 using 2 N NaOH.  
Again the solution was centrifuged under the above-mentioned conditions and upon 
completion the supernatant was aliquotted, labeled, and frozen at -20°C.  For the 
measurement of lipolytic activity a volume of 0.5 ml tributyrin was added to 14.5 ml of 
0.28 mM Tris-HCl, 1.4 mM CaCl2, 4.0 mM taurodeoxycholate, 150 mM NaCl, pH 8.0 
in a reaction vessel kept at 37°C.  Fifty microliters of the acidic feline colipase 
preparation was also added to the vessel and the pH was adjusted to 8.0 with the use of 
100 mM NaOH.  Once the pH in the vessel was at 8.0, 10 µl of the sample were added 
and the pH was kept at 8.0 by the controlled addition of 100 mM NaOH.  After a waiting 
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period of 1 min, the amount of NaOH added was measured for 3 min and lipolytic 
activity was expressed in international units with 1 unit representing the amount of 
lipolytic activity releasing 1 mmol of titratable fatty acid per minute under above-
mentioned conditions. 
Preparation of pancreatic extract - Pancreata were collected from cats 
sacrificed for unrelated projects and kept frozen at -20°C until they were used for 
extraction.  For the pancreatic extraction, the pancreatic tissue was thawed at room 
temperature and the gross fat was removed with a razor blade.  The partially delipidated 
pancreatic tissue was then cut into small pieces, mixed thoroughly with a tissue grinder 
(Polytron, Brinkmann Instruments, Westbury, NY), and delipidated with the use of 
organic solvents.  The solvents used were acetone, chloroform, 1-butanol, and ethyl 
ether.  Prior to the delipidation procedure, all solvents were kept at 4°C.  All organic 
solvents used were handled in a well ventilated fume hood.  Three large feline pancreata 
were soaked in 100 ml acetone and minced with a tissue grinder.  The pancreatic 
material was then transferred to a medium Buchner funnel and filtered to dryness with 
vacuum suction.  The solvent was discarded.  The filtrate was mixed two more times in 
100 ml of acetone and filtered to dryness each time with a medium Buchner funnel.  
Each time the solvent was discarded.  The filtrate was further delipidated by immersing 
the pancreatic material in 200 ml of a 9 to 1 mixture of chloroform and 1-butanol and 
mixing thoroughly with a tissue grinder followed by filtration to dryness with a medium 
Buchner funnel.  This process was completed two more times, with the solvent being 
discarded after each filtration step.  The pancreatic material was further delipidated by 
  
12 
mixing with 200 ml of a 4 to 1 mixture of chloroform and 1-butanol with a tissue grinder 
and filtered to dryness.  This step was completed one more time as described above.  
Lastly, the filtrate was carefully dissolved in ethyl ether and mixed with a spatula for 
approximately two minutes and then filtered to dryness through the medium Buchner 
funnel.  Once the filtrate was completely dry, it was broken up into a fine powder and 
this delipidated pancreatic extract was kept at -20°C until the protein extraction 
procedure. 
Protein extraction -  Two grams of delipidated pancreatic extract was weighed 
out and combined with 250 µl of 100 mM PMSF in isopropyl alcohol.  Immediately, 25 
ml of 20 mM Tris-HCl, 2 mM benzamidine, 150 mM NaCl, pH 7.5 was added to this 
mixture in a centrifuge tube and mixed thoroughly for 1 min with a tissue homogenizer.  
Benzamidine and PMSF were both used as protease inhibitors.  Then the mixture was 
put onto a rocking plate and mixed for 20 min at 4°C.  The mixture was then centrifuged 
for 15 min at 10,000 g and 4°C.  The supernatant was evaluated for absorbance at 280 
nm, evaluated for lipolytic activity, and saved in the refrigerator.  Another 25 ml of 20 
mM Tris-HCl, 2 mM benzamidine, 150 mM NaCl, pH 7.5 and 250 µl of 100 mM PMSF 
in isopropyl alcohol was added to the precipitate and mixed again with the tissue 
homogenizer, the rocking plate, and centrifuged under the same conditions as above.  
The supernatant was again evaluated for absorbance at 280 nm and lipolytic activity and 
then combined with the supernatant from the first extraction step.  This extraction 
procedure was carried out a third time and the supernatant was analyzed as above and 
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combined with the supernatant from the first two extraction steps.  The final precipitate 
was discarded. 
Buffer exchange -  The buffer of the pooled supernatant was changed to 10 mM 
Tris-HCl, 2 mM benzamidine, 1 mM PMSF, pH 8.0 (buffer A) before application to the 
anion-exchange column.  This was accomplished by using a disposable gel-filtration 
column (PD-10®, Amersham Pharmacia Biotech, Piscataway, NJ) at 4°C following the 
manufacturer's instructions.  The column was first drained of the storage solution and 
then washed with 20 ml of buffer A.  Non-specific binding sites were then blocked by 
washing the column with 20 ml of buffer A containing 0.1 g/ml bovine serum albumin, 
and washed again with 20 ml of buffer A.  The next step was to add 3 ml of supernatant 
and discard the eluent, followed by the addition of 4 ml of buffer A and collection of the 
eluent.  The column was washed again with 20 ml of buffer A and the eluent was 
discarded.  After this, the column was ready for another cycle of buffer exchange.  This 
process was carried out until all of the pooled supernatant had been applied to the 
column.  To speed up the process four columns were used simultaneously. 
Anion-exchange chromatography -  For further purification by anion-exchange 
chromatography, feline PL was applied to a pre-packed Mono Q® column (bed height 
100 mm, column diameter 10 mm) in buffer A.  The column was washed until the 
absorbance monitor at a wavelength of 280 nm had returned to base-line.  Then the 
feline PL mixture was eluted using a continuous NaCl gradient from 0 to  80 mM NaCl 
in buffer A at a flow rate of 1 ml/min for 30 min.  Fractions were collected in 5 ml 
aliquots and those fractions suspected of lipase activity were analyzed.  Fractions with 
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high lipolytic activity were collected, pooled, concentrated, and the buffer was changed 
to 10 mM MES, 2 mM benzamidine, 1 mM PMSF, pH 6.0 using a concentrating device 
(Ultrafree® 10K concentrator; Millipore Corporation, Bedford, MA).  The concentrated 
fraction was then saved for further purification. 
Size-exclusion chromatography - The next purification step of feline PL was 
carried out on a Sephacryl S-300 HR® size-exclusion chromatography column (bed 
height 600 mm, column diameter 16 mm).  Feline PL was applied to the column in 10 
mM MES, 2 mM benzamidine, 1 mM PMSF, pH 6.0 at a flow rate of 1 ml/min.  
Fractions were collected in 5 ml aliquots and those fractions suspected of lipase activity 
were analyzed.  Fractions with high lipolytic activity were collected, pooled, 
concentrated, and the buffer was changed to 10 mM MES, pH 6.0 by means of an 
Ultrafree® 10K concentrator.  This fraction was then saved for further purification. 
Cation-exchange chromatography -  The final purification step utilized cation-
exchange chromatography to further purify feline PL.  This was done with a self-packed 
Source S® column (bed height 100 mm, column diameter 10 mm).  The feline PL 
preparation from the previous purification step was applied to the column in 10 mM 
MES, pH 6.0 at a flow rate of 1 ml/min.  After the absorbance monitor at a wavelength 
of 280 nm had returned to the base-line a linear NaCl gradient from 0 to 200 mM NaCl 
in 10 mM MES, pH 6.0 was applied over 60 min at a flow rate of 1 ml/min to elute the 
feline PL mixture.  For this last purification step 2.5 ml fractions were collected and 
analyzed for lipase activity.  The fraction determined to have the greatest lipase activity 
was collected, concentrated, and the buffer was changed to phosphate buffered saline 
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(100 mM sodium phosphate, 150 mM NaCl, pH 7.2) using an Ultrafree® 10K 
concentrator.  Once the buffer had been changed, the absorbance of the purified feline 
PL was adjusted to A280 = 0.59, then aliquotted and frozen at -80°C. 
Partial characterization -  The molecular mass of the purified feline PL was 
estimated using a SDS-PAGE protocol following manufacturer's directions.  The gel was 
stained with a Coomassie blue type stain (GelCode® blue, Pierce Chemical Company, 
Rockford, IL) for estimation of molecular mass.  For a more exact determination of 
molecular mass a sample was sent to the Mass Spectrometry Laboratory, Department of 
Chemistry, Texas A&M University, College Station, TX.  The specific absorbance of 
fPL was determined by measurement of the protein concentration of a serial dilution of a 
solution of fPL in PBS, pH 7.2 with a known absorbance at a wavelength of 280 nm 
using a BCA protein assay.58  An Edman degradation procedure utilizing an automated 
amino acid sequence analyzer was used in order to determine the N-terminal amino acid  
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sequence of the first 25 amino acid residues.  The Edman degradation procedure was 
conducted by the Department of Biochemistry, Purdue University, West-Lafayette, IN. 
 
RESULTS 
Feline PL was successfully purified from feline pancreatic tissue by delipidation, 
protein extraction, anion-exchange chromatography (Fig 1), size-exclusion 
chromatography (Fig 2), and cation-exchange chromatography (Fig 3).  The overall yield 
of the purification protocol was 18.6% (Table 1).  The approximate specific absorbance 
at 280 nm of fPL was 1.18 for a 1 mg/ml sample (Table 2).  Analysis of the purified fPL 
upon sodium dodecyl sulfate polyacrylamide gel electrophoresis showed a single band 
with an estimated molecular mass of 52.5 kDa (Fig 4).  The exact molecular mass was 
determined to be 52.4 kDa by mass spectrometry.  Edman degradation analysis 
determined the N-terminal amino acid sequence of the first 25 amino acid residues as 
Lys–Glu–Ile-?–Phe–Pro–Arg–Leu–Gly-?–Phe–Ser–Asp–Asp–Ala–Pro–Trp–Ala–Gly-
Ile-Ala-Gln-Arg-Pro-Leu (positions indicated with ? could not be determined; Table 3). 
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Figure 1-Anion-exchange chromatography of aqueous feline pancreatic extract. This figure shows a representative 
chromatogram after anion-exchange chromatography of the aqueous pancreatic extract after buffer exchange using a PD-10® 
column. The blue line depicts the absorbance at a wavelength of 280 nm during chromatography. The green line shows the 
concentration of NaCl. The pink numbers show the beginning of each collected fraction. The arrow marked fPL points to the 
only peak that contained lipolytic activity. Column: Mono Q® (pre-packed); flow rate: 1 ml/min; mobile phase: 10 mM Tris-
HCl, 2 mM benzamidine, 1 mM PMSF, pH 8.0. 
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Figure 2-Size-exclusion chromatography of partially purified feline pancreatic lipase. This figure shows a representative 
chromatogram after size-exclusion chromatography of partially purified feline PL. The blue line depicts the absorbance at a 
wavelength of 280 nm during chromatography. The pink numbers show the beginning of each fraction collected. The arrow 
points to the peak with lipolytic activity. Column: Sephacryl S-300 HR® (pre-packed); flow rate: 1 ml/min; mobile phase: 10 
mM MES, 2 mM benzamidine, 1 mM PMSF, pH 6.0. 
fPL 
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Figure 3-Cation-exchange chromatography of partially purified feline pancreatic lipase. This figure shows a representative 
chromatogram after cation-exchange chromatography of partially purified feline PL. The blue line depicts the absorbance at a 
wavelength of 280 nm during chromatography. The green line shows the concentration of NaCl.  The pink numbers show the 
beginning of each fraction collected. The arrow points to the peak with lipolytic activity. Column: Source S® (self-packed); 
flow rate: 1 ml/min; mobile phase: 10 mM MES, pH 6.0. 
fPL 
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Table 1-Purification of fPL.  This table presents the data obtained throughout the purification procedure of fPL.  With this data 
it is possible to see how much lipolytic activity is present after each step in the process.  The protein content was estimated 
using a specific absorbance of A280=1.18 for feline PL.  The data shown for the post cation-exchange chromatography row was 
obtained after the concentration procedure, buffer change to PBS, pH 7.2, and the adjustment of the remaining sample to 
A280=0.550. 
 
 
 
 
 
 
 
Purification Stage Volume 
(ml) 
A280 Protein 
Content (mg) 
Specific 
Lipolytic 
Activity (U/mg) 
Total 
Lipolytic 
Activity (U) 
Yield 
(%) 
Aqueous pancreatic extract 136.5 6.821 789.0 126 99,474 100.0 
Post buffer exchange 228.0 2.746 530.5 147 77,963 78.4 
Post anion-exchange 
chromatography 
32.5 0.798 22.0 2732 60,105 60.4 
Post-gel-filtration chromatography 10.0 0.582 4.9 6001 29,405 29.6 
Post cation-exchange 
chromatography 
3.85 0.550 1.8 10,261 18,470 18.6 
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Table 2-Specific absorbance of fPL.  This table shows the results for the estimation of the specific absorbance for fPL.  A 
solution of fPL in PBS, pH 7.2 with and absorbance of A280=0.55 was used as the starting solution and was analyzed in a BCA 
protein assay. 
 
 
 
 
 
 
 
Dilution Factor A280 Assay Result 
(μg/ml) 
Adjusted Result 
(μg/ml) 
Specific Absorbance 
1 0.550 472.86 472.86 1.163 
2 0.275 227.67 455.34 1.208 
4 0.1375 118.30 473.20 1.162 
Mean    1.178 
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Figure 4-SDS-PAGE of feline classical pancreatic lipase.  This NuPAGE 10% Bis-Tris 
gel was stained with a Coomassie blue stain.  Purified feline classical PL (fPL) was 
loaded in lane 1.  A molecular weight standard was loaded in lane 2.  The molecular 
weight of the purified feline classical PL was estimated to be 52.5 kDa. 
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Table 3-N-terminal amino acid sequence comparison of fPL with other species.  This table shows the N-terminal amino acid 
sequence of feline PL (fPL), porcine pancreatic lipase (pPL), canine pancreatic lipase (cPL), canine pancreatic lipase related 
protein 1 (cPLRP1), equine pancreatic lipase (ePL), and human pancreatic lipase (hPL).  The amino acid sequences for ePL 
and hPL were predicted from cDNA sequence analysis.  The three-letter code is used for amino acid identification.  Amino 
acid residues that could not be identified are represented with '?'.  The amino acid residues shown in blue are non-homologous 
with feline PL. 
 
 
 
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
                            
fPL Lys Glu Ile ? Phe Pro Arg Leu Gly ? Phe Ser Asp Asp Ala Pro Trp Ala Gly Ile Ala Gln Arg Pro Leu 
                            
pPL Ser Glu Val Cys Phe Pro Arg Leu Gly Cys Phe Ser Asp Asp Ala Pro Trp Ala Gly Ile Val Gln Arg Pro Leu 
                            
cPL Lys Glu Val Cys Phe Pro Arg Leu Gly Cys Phe Ser Asp Asp Ser Pro Trp Ala Gly Ile Val Glu Arg Pro Leu 
                            
cPLRP1 Lys Glu Val Cys Tyr Glu Gln Ile Gly Cys Phe Ser Asp Ala Glu Pro Trp Ala Gly Thr Ala Ile Arg Pro Leu 
                            
ePL Asn Glu Val Cys Tyr Glu Arg Leu Gly Cys Phe Ser Asp Asp Ser Pro Trp Ala Gly Ile Val Glu Arg Pro Leu 
                            
hPL Lys Glu Val Cys Tyr Glu Arg Leu Gly Cys Phe Ser Asp Asp Ser Pro Trp Ser Gly Ile Thr Glu Arg Pro Leu 
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DISCUSSION 
This is the first detailed description of the purification of feline PL.  Classical PL 
has previously been purified from many other vertebrate species.59-66  However, many of 
the previous purification protocols described the purification of PL from pancreatic 
juice.  This method was initially developed because aqueous extractions of pancreatic 
tissue led to the formation of a macromolecular form of PL, known as fast lipase.  Fast 
lipase is a macromolecular aggregate consisting of PL, colipase, and lipids.30  In order to 
collect the pancreatic juice, the pancreatic duct must be cannulated, which raises animal 
use concerns, especially when a non-invasive alternative such as the purification from 
pancreatic tissue collected from cats euthanized for unrelated projects exists.  Using the 
delipidation procedure described in the materials and methods section it was possible to 
purify fPL from pancreatic tissue without the formation of fast lipase. 
Reports of the specific absorbance of PL in any species could not be found.  A 
BCA-based protein assay was used to estimate the protein content in a solution of pure 
fPL with a known absorbance at a wavelength of 280 nm.58  Bovine serum albumin was 
used as a standard in this assay.  Although, different proteins may have a different 
relative response in the BCA assay the determination of specific absorbance of fPL 
through the use of this assay may be inaccurate.58  The estimated specific absorbance of 
fPL reported here can be used as a reproducible reference point for future studies 
involving feline PL. 
A sample of purified feline PL showed a single band on SDS-PAGE when 
stained with a Coomassie blue stain.  The molecular mass of fPL as determined by mass 
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spectrometry was 52.4 kDa.  This value is comparable to other values reported for PL 
such as 52 kDa reported for porcine PL, 50.7 kDa reported for canine PL, 48 kDa 
reported for both human and chicken PL, and 45 kDa reported as the molecular mass of 
dromedary PL.63,65-68 
The first 25 amino acid residues of the N-terminal amino acid sequence were 
identified except for two residues.  A comparison of the sequence for the 23 identified 
amino acid residues of feline classical PL showed a sequence homology of 87% with 
porcine classical PL, 83% with canine classical PL, 74% with equine classical PL, 70% 
with human classical PL, and 61% with canine pancreatic lipase related protein 1 (Table 
3).19,66,69-71  The two amino acid residues that could not be determined were in positions 
4 and 10.  In pigs, dogs, horses, and human beings these two residues have both been 
shown to be cysteine residues.  Cysteines can form disulfide bridges to form cystine that 
cannot easily be elucidated during amino acid sequencing.  Therefore, it is hypothesized 
that the amino acid residues in positions 4 and 10 of fPL are cysteine as well.  However, 
this hypothesis has yet to be proven by repeated amino acid sequencing. 
In conclusion, this is the first detailed report of the purification of feline classical 
PL from cat pancreas.  Feline PL as reported here shares many characteristics with 
classical PL previously purified in other species. 
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CHAPTER III 
DEVELOPMENT AND VALIDATION OF A RADIOIMMUNOASSAY FOR 
FELINE PANCREATIC LIPASE IMMUNOREACTIVITY (fPLI) 
 
INTRODUCTION 
The development of radioimmunoassay technology by Yalow and Berson in 
1960 was a major step for the diagnostic capabilities of physicians and also 
veterinarians.72  Yalow and Berson conducted research on diabetes mellitus that led to 
the discovery of the formation of anti-insulin antibodies in diabetic patients treated with 
exogenous insulin.73  This discovery led to the development of radioimmunoassays.  
Since then over 80,000 scientific papers have been written on this topic and many 
radioimmunoassays for the measurement of different analytes have been developed.  A 
common feature that these assays share is that the target molecule has a relatively high 
molecular mass, thus facilitating the production of antiserum.  The general principles of 
radioimmunoassays are simple.  The target substance is radiolabeled with 125I to achieve  
efficient detection.  The radioactive tracer is commonly produced using the chloramine T 
method first described by Hunter and Greenwood.74  For the assay a known amount of 
the radioactive tracer and a known amount of antiserum are placed into a test tube and 
either a known amount of unlabeled target substance (standard) or a plasma, serum, or 
other biological fluid sample with an unknown amount of the target substance is added.  
The radioactively labeled tracer competes with the unlabeled target substance in the 
standard or sample and forms immune complexes.  Bound and unbound tracer are then 
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separated and the radioactivity of the bound fraction is determined by measuring the 
radioactivity of the sample with a gamma counter.  When the concentration of target 
substance in the standard or sample solution is low the number of bound counts is high.  
In contrast, when the concentration of target substance in the standard or sample solution 
is high the number of bound counts is low.  After evaluating a range of standard 
solutions, a standard curve can be generated and unknown samples can be measured by 
comparison with the standard curve. 
Pancreatitis used to be diagnosed infrequently in cats.  Recent studies have 
shown that pancreatitis occurs frequently in cats, which has led to an increased level of 
suspicion by veterinary clinicians.49  However, definitive diagnosis of feline pancreatitis 
remains elusive and a minimally-invasive diagnostic test that is both highly sensitive and 
specific for feline pancreatitis is needed. 
This is the first detailed report of the development and validation of a 
radioimmunoassay for the measurement of concentrations of feline PL in biological 
samples. 
 
MATERIALS AND METHODS 
Materials -  All commonly used research materials and supplies were purchased 
from VWR Scientific, West Chester, PA.  Radioactive iodine (125I) was from NEN Life 
Sciences Products, Inc., Boston, MA.  Precipitation solution (N6) was from Diagnostic 
Products Corporation, Los Angeles, CA.  The gamma counter (Riastar) used was from 
Packard Instrument Company, Meriden, CT. 
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Antibody production -  Polyclonal antibody production was conducted at 
Lampire Biological Laboratories, Inc. (LBL) in Pipersville, PA following their Express-
Line PLUS protocol using New Zealand White rabbits.  Feline PL was prepared in 
phosphate buffered saline, pH 7.2 and sent to LBL for antibody production.  Two rabbits 
were used and both were inoculated with 0.25 mg fPL in 0.5 ml PBS emulsified with 0.5 
ml Complete Freund’s adjuvant.  Three weeks after the first injection, each rabbit 
received another injection of 0.25 mg fPL in 0.5 ml PBS emulsified with an equal 
volume of Incomplete Freund’s adjuvant.  After another three week period, each rabbit 
was again injected with 0.25 mg fPL in 0.5 ml PBS emulsified with 0.5 ml Incomplete 
Freund’s adjuvant.  A production bleed was completed one week after the last booster 
and produced 47 ml of serum between the two rabbits.  An exsanguination bleed was 
performed two weeks after the last booster and the yield was 181 ml of serum between 
the two rabbits. 
Radioiodination -  For the radioimmunoassay, tracer was produced by 
iodination of feline PL with 125I, using the chloramine T method.74  A mini stir bar (8 
mm x 1.5 mm) was placed in a polypropylene test tube (75 mm x 12 mm) that was 
situated over a stir plate.  Then 10 µl of free 125I (NaI, 0.1 mCi/µl at time of production) 
were added to the test tube using a Hamilton syringe and mixed with 10 µl 250 mM 
sodium phosphate buffer, pH 7.5.  This was followed by the addition of 10 µl of purified 
feline PL in 10 µl PBS, pH 7.2, 10 µl of 2 mg/ml chloramine T in 50 mM sodium 
phosphate, pH 7.5, 100 µl of 400 mg/ml sodium metabisulfite in 50 mM sodium 
phosphate, pH 7.5, and 860 µl of 2 mg/ml potassium iodide in 50 mM sodium 
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phosphate, pH 7.5 in rapid succession.  The iodinated protein fraction was separated 
from the free iodide by size-exclusion chromatography on a disposable column (PD-10, 
Amersham Pharmacia Biotech, Piscataway, NJ) following the manufacturer’s directions.  
Radioimmunoassay buffer (RIAB, 50 mM sodium phosphate, pH 7.5, with 5 g/L bovine 
serum albumin and 0.2 g sodium azide) was used as the mobile phase.  Fractions of 1 ml 
each were collected and the fraction containing the peak protein concentration was 
collected.  The tracer was adjusted to approximately 40,000 counts/minute/100 µl tracer 
and kept in a lockable refrigerator at 4°C until further use. 
fPLI-RIA procedure -  Polypropylene tubes were labeled in duplicate fashion.  
The first two tubes were labeled TC (total count) and each received 100 µl tracer.  The 
next two tubes labeled NB (nonspecific binding) received 100 µl tracer and 200 µl 
radioimmunoassay buffer (RIAB), followed by two tubes labeled B0 (reference) that 
received 100 µl tracer, 100 µl anti-fPL antibody solution (approximately 1 mg/ml 
purified anti-fPL antibody diluted at 1 in 16,000 with RIAB), and 100 µl RIAB.  The 
following 14 tubes were used for the standards and received 100 µl tracer, 100 µl 
antibody solution, and 100 µl standard solution of 128, 64, 32, 16, 8, 4, or 2 µg/L fPL in 
RIAB.  All of the following tubes were used for unknown samples and received 100 µl 
tracer, 100 µl antibody solution, and 100 µl of the unknown sample.  Tubes were 
vortexed and incubated for 2 hours at room temperature.  After the incubation, all tubes, 
except the tubes labeled TC, received 100 µl rabbit carrier serum (1 ml normal rabbit 
serum mixed with 99 ml RIAB) and 1 ml of a commercially available precipitation 
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solution (N6) containing anti-rabbit IgG antibodies.  Again, all tubes were vortexed and 
then centrifuged at 3000 g and 4°C for 20 min.  The supernatant of all tubes, except the 
tubes labeled TC, was carefully decanted and all tubes were counted for 1 min in a 
gamma counter.  A standard curve was calculated using a log/logit curve fit.  The fPL 
concentrations were plotted along the x-axis in a logarithmic fashion.  Values on the y-
axis were calculated using the formula y = loge((Bstandard/B0)/(1-(Bsample/B0)) with Bstandard 
being the counts per minute (CPM) for each standard and B0 being the CPM for the 
reference. 
fPLI-RIA validation -  This assay was validated by determination of assay 
sensitivity, control range, linearity, accuracy, precision, and reproducibility by testing 
assay sensitivity, dilutional parallelism, spiking recovery, intra-assay variability, and 
inter-assay variability.  Assay sensitivity was determined by setting up 10 duplicates of 
B0 and calculating the standard deviation of the raw counts of these 10 duplicates.  Three 
standard deviations were subtracted from the mean count and the resulting value 
evaluated on the standard curve.  The sensitivity also served as the lower limit of the 
working range.  Serum samples were selected from random feline serum samples to fall 
into different areas of the working range of the assay.  Because a volume of 1 ml or 
greater was not available for most serum samples, samples used for validation were 
generated from a pool of several serum samples.  For dilutional parallelism, 4 serum 
samples were evaluated at full strength and at dilutions of 1 in 2, 1 in 4, and 1 in 8.  
Spiking recovery was determined by adding 0, 2, 4, 6, 8, 16, 32, and 64 µg/L fPL in 
RIAB to each one of 4 serum samples.  Intra-assay variability was determined by 
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evaluating four different serum samples 10 times within the same assay run.  Finally, 
inter-assay variability was determined by evaluating four different samples in 10 
consecutive assay runs.  The control range for the radioimmunoassay for fPLI was 
determined from the central 95th percentile (2.5th to the 97.5th percentile) of serum fPLI 
concentration in 30 clinically healthy cats. 
 
RESULTS 
A typical standard curve used for the analysis of feline pancreatic lipase 
immunoreactivity (fPLI) by radioimmunoassay is shown in Figure 5.  The sensitivity of 
the assay was calculated to be 1.2 µg/L, leading to a lower limit of the working range of 
1.2 µg/L.  Observed to expected ratios for dilutional parallelism of 4 serum samples 
ranged from 58.0 to 164.3% (Table 4).  Observed to expected ratios for spiking recovery 
of 4 serum samples ranged from 76.0 to 156.5% (Table 5).  Coefficients of variation for 
intra-assay variability of the 4 serum samples were 10.1, 4.5, 2.2, and 3.9% (Table 6).  
Finally, coefficients of variation for inter-assay variability of the 4 serum samples were 
24.4, 15.8, 16.6, and 21.3% (Table 7).  The control range established from the central 
95th percentile of serum fPLI in 30 clinically healthy cats was 1.2 to 3.8 µg/L (Fig 6). 
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Figure 5-Typical standard curve of fPLI-RIA.  This figure shows a typical standard curve for a radioimmunoassay for fPLI.  
The seven standard concentrations are 2, 4, 8, 16, 32, 64, and 128 μg/L, which are marked on the x-axis in a logarithmic 
fashion.  %B/B0 values are displayed on the y-axis as counts per minute (CPM) and are calculated from y = 
loge((Bstandard/B0)/(1-(Bsample/B0))).  The CPM values must be multiplied by a factor of 10,000 to obtain the actual results. 
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Table 4-Dilutional parallelism of radioimmunoassay for fPLI.  This table shows data 
from serial dilution of 4 serum samples throughout the control range of the assay.  All 4 
serum samples were measured in dilutions of 1 in 1, 1 in 2, 1 in 4, and 1 in 8.  The 
observed to expected ratios (O/E) are shown as % in bold print. 
 
 
 
 
Dilution Observed Value 
(µg/L)
Expected Value 
(µg/L)
O/E (%)
Sample 1 1 in 1 4.48
1 in 2 3.5 2.24 156.3
1 in 4 1.28 1.12 114.3
1 in 8 0.92 0.56 164.3
Sample 2 1 in 1 7.53
1 in 2 3.95 3.77 104.9
1 in 4 2.2 1.88 116.9
1 in 8 0.93 0.94 98.8
Sample 3 1 in 1 45.06
1 in 2 24.45 22.53 108.5
1 in 4 11.9 11.27 105.6
1 in 8 6.47 5.63 114.9
Sample 4 1 in 1 115.79
1 in 2 53.04 57.9 91.6
1 in 4 20.69 28.95 71.5
1 in 8 8.4 14.47 58
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Table 5-Spiking recovery of radioimmunoassay for fPLI.  This table shows the data 
obtained from the spiking recovery performed on 4 different serum samples throughout 
the control range.  The observed to expected ratios (O/E) are shown as % in bold print. 
 
 
 
 
Concentration
added (µg/L)
Sample 1 0 2.7
2 5.1 4.7 108.6
4 8 6.7 119.9
8 13 10.7 121.6
16 26.3 18.7 141
32 48.8 34.7 140.8
64 104.4 66.7 156.5
Sample 2 0 3
2 4.1 5 81.3
4 5.8 7 82.2
8 9.2 11 83.1
16 14.6 19 76.9
32 27.9 35 79.6
64 51 67 76
Sample 3 0 16.9
2 22.3 18.9 118
4 26.2 20.9 125.4
8 29.8 24.9 119.8
16 43.7 32.9 132.8
32 72.2 48.9 147.6
64 124.5 80.9 153.9
Sample 4 0 35.9
2 51.1 37.9 134.8
4 53.4 55.1 96.9
8 62.8 61.4 102.3
16 85.1 78.8 108
32 121.9 117.1 104.1
64 214.7 185.9 115.1
Observed (µg/L) Expected (µg/L) O/E (%)
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Table 6-Intra-assay variability of radioimmunoassay for fPLI.  This table shows the 
results obtained from the intra-assay variability of the radioimmunoassay for fPLI using 
4 different serum samples.  (SD = standard deviation; CV = coefficient of variation; 
CV(%) = (SD/Mean)*100). 
 
 
 
 
 
 
 
 
Table 7-Inter-assay variability of radioimmunoassay for fPLI.  This table shows the 
results obtained from the inter-assay variability of the radioimmunoassay for fPLI using 
4 different serum samples.  (SD = standard deviation; CV = coefficient of variation; 
CV(%) = (SD/Mean)*100). 
 
 
 
 
Sample 1 Sample 2 Sample 3 Sample 4
Number of 
Repeats
10 10 10 10
Mean 
(µg/L)
3.35 7.51 19.82 39.78
SD (µg/L) 0.34 0.33 0.44 1.54
CV (%) 10.1 4.5 2.2 3.9
Sample 1 Sample 2 Sample 3 Sample 4
Number of 
Repeats
10 10 10 10
Mean 
(µg/L)
3.8 6.98 27.75 57.4
SD (µg/L) 0.93 1.1 4.62 12.23
CV (%) 24.4 15.8 16.6 21.3
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Figure 6-Mean serum concentration for fPLI in 30 clinically healthy cats  The mean 
serum concentration for fPLI as measured in 30 clinically healthy cats was 2.18 +/- 
0.975 μg/L. The control range was determined from the central 95th percentile to be 1.2 
to 3.8 μg/L.  The mean fPLI concentration is depicted by the solid line.  The control 
range is shown between the dotted lines. 
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DISCUSSION 
A radioimmunoassay for the measurement of feline pancreatic lipase 
immunoreactivity (fPLI) in cat serum was successfully established.  Although many 
radioimmunoassays have been developed for use in both human and veterinary 
medicine, there is still very little known about the minimal performance characteristics 
for a clinically useful assay.75,76,77-79  Most investigators simply state the performance 
characteristics of the assay they develop and validate.80,81,82  Other investigators have 
targeted observed to expected ratios for dilutional parallelism and spiking recovery 
between 80 to 120% but references are not provided as to the reason for these targeted 
values.76  Also, some authors target coefficients of variation for intra-assay and inter-
assay variability to reach a maximum of 10 to 15%, but again there is no rationale given 
for this target value.76  However, while there is little evidence to suggest the validity of 
these targeted performance criteria many radioimmunoassays that have proven to be 
clinically relevant have shown performance criteria meeting these values.76 
Observed to expected ratios for serial dilution ranged between 58.0 and 164.3%.  
The observed to expected ratios for sample 1 were elevated above 120% for the 1 in 2 
and 1 in 8 dilution.  The dilution of 1 in 4 for sample 1 was between the performance 
indices.  The observed to expected ratios for sample 2 and sample 3 fall into the targeted 
range of values for a clinically relevant assay.  The first dilution step for sample 4 falls 
nicely into the desired range of observed to expected ratios, but the second and third 
dilution steps have ratios less than 80%.  The data presented suggests that the assay has 
limited linearity. 
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Observed to expected values for spiking recovery were between 76.0 and 
156.5%.  The observed to expected ratios for sample 1 are within the range of 80 to 
120% for the first three spiking steps, but begin to increase outside the range when larger 
amounts of protein are added to the sample.  The observed to expected ratios for sample 
2 are within the desired range for the first three spiking steps, and drop slightly below 
the 80% marker for the last three steps when larger amounts of protein are added.  The 
data obtained for sample 3 is very similar to sample 1 in that the first three steps are very 
close to the desired range, while the last three steps have elevated observed to expected 
ratios.  All of the observed to expected ratios for sample 4 fall into the desired range 
except the first sample that was spiked with 2 μg/L of fPL protein.  This value for the 
first step of sample 4 could be attributed to assay variability because the data shows that 
51.1 μg/L was observed when only 37.9 μg/L was present.  Granted, some of these 
values are outside the range of 80 to 120%, but this is usually only the case when large 
amounts of fPLI are added to the samples. The data presented for spiking recovery 
suggest that the assay is accurate. 
The control range of the assay was calculated to be 1.2 to 3.8 μg/L from the 
central 95th percentile of serum fPLI concentrations in 30 clinically healthy cats. 
The coefficients of variation (CVs) for the intra-assay variability for 3 of the 4 
serum samples were well below 10% and the fourth value was just out of range at 
10.1%.  These values suggest that the assay is sufficiently precise for clinical use.  The 
CVs for inter-assay variability of the four serum samples were 24.4, 15.8, 16.6, and 
21.3%.  The CV for sample 1 is higher than desired, but was accepted because the value 
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of sample 1 falls in the low area of the working range.  The CV for sample 4 was also 
higher than desired and accepted because the value of sample 4 falls in the high area of 
the working range.  The data obtained from inter-assay variability suggests that the assay 
has a limited reproducibility in the upper and lower areas of the working range. 
In conclusion, the radioimmunoassay described here is sufficiently accurate and 
precise for clinical use, with a limited linearity and reproducibility in the upper and 
lower areas of the working range.  Clinical studies will be necessary in order to 
determine whether this degree of assay linearity and reproducibility will be sufficient to 
definitively distinguish cats with pancreatitis from clinically healthy cats. 
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CHAPTER IV 
MEASUREMENT OF SERUM fPLI AND fTLI CONCENTRATIONS IN CATS 
WITH EXPERIMENTALLY INDUCED PANCREATITIS 
 
INTRODUCTION 
Several hundred thousand cases of pancreatitis are diagnosed each year in the 
United States alone.  It has been estimated that almost 90% of all the human pancreatitis 
cases remain undiagnosed.  Pancreatitis also commonly occurs in both dogs and cats.  It 
can be assumed, that as in human beings, canine and feline pancreatitis remain 
undiagnosed in many cases.  This could be because of the nonspecific clinical symptoms 
presented by canine and feline patients with pancreatitis combined with the lack of a 
clinically useful diagnostic test that is both highly sensitive and specific for pancreatitis. 
Studies performed in dogs and human beings with pancreatitis have shown 
increases in serum amylase and lipase activities.83,84  However, serum amylase and 
serum lipase activities have been shown to have no clinical usefulness for the diagnosis 
of feline pancreatitis.  Many of the reports that have been published regarding cats with 
pancreatitis describe a very vague clinical picture.50,85,86 
Recently, a new diagnostic test for exocrine pancreatic disease in cats, feline 
trypsin-like immunoreactivity assay (fTLI) has been described.87  The reference range 
for fTLI is between 12.0 – 82.0 μg/L.  A serum fTLI concentration equal to or below 8.0 
μg/L is diagnostic for EPI, while concentrations between 8.0 and 12.0 μg/L are 
equivocal.88  A serum fTLI in excess of 100.0 μg/L is consistent with either acute or 
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chronic pancreatitis or decreased renal excretion caused by severe renal insufficiency.89  
The measurement of serum fTLI concentration is highly specific for pancreatitis, but the 
sensitivity of the assay is less than optimal.  Therefore, a new diagnostic test for feline 
pancreatitis that is both highly sensitive and specific is highly desirable. 
As described previously, the control range for the radioimmunoassay for the 
measurement of serum fPLI concentration in cat serum was established as 1.2-3.8 μg/L. 
This study was completed in order to compare the clinical utility of serum fPLI 
and fTLI concentrations for the diagnosis of pancreatitis in the cat. 
 
MATERIALS AND METHODS 
Serum samples -  All serum samples that were used for this comparison study 
were obtained from remaining serum from a previous research project relating to feline 
pancreatitis.  The samples that were used for this project came from cats with 
experimentally induced pancreatitis.  The pancreatitis was induced by retrograde 
injection of oleic acid into the pancreatic duct.  Cat 1, cat 2, and cat 3 had serum samples  
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collected at 0, 8, 24, 48, 72, 96, 120, 144, 192, 240, 288, 384, and 480 hours after 
induction of pancreatitis.  Cat 4 had serum samples collected at 0, 8, 24, 48, 72, 96, 120, 
144, 192, and 240 hours after induction of pancreatitis. 
Assays -  All of the serum samples were previously analyzed for feline trypsin-
like immunoreactivity (fTLI) at the Gastrointestinal Laboratory, Department of Small 
Animal Medicine and Surgery, Texas A&M University, College Station, TX using an in-
house enzyme-linked immunosorbent assay (ELISA).  All of the serum samples were 
also analyzed for feline pancreatic lipase immunoreactivity (fPLI) using the newly 
developed and validated radioimmunoassay using the protocol described in Chapter III. 
 
RESULTS 
Serum fTLI concentration as measured by ELISA and serum fPLI concentration 
as measured by RIA were successfully measured in 4 cats with experimentally induced 
pancreatitis (Table 8).  Serum fPLI and fTLI concentrations were compared for each 
time point and each cat (Figs 7 to 10). 
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Table 8-Serum fPLI (μg/L) and fTLI (μg/L) concentrations in 4 cats with experimentally induced pancreatitis.  Serum fPLI 
concentration as measured by RIA and serum fTLI concentration as measured by ELISA were measured in 4 cats with 
experimentally induced pancreatitis and compared over time.  There was no serum sample available to analyze the fPLI 
concentration for cat 4 for the 120 hour collection time and the 240 hour data point was the last time serum was collected from 
cat 4.  The control range for serum fPLI is  1.2-3.8 μg/L, the reference range for serum fTLI is 12.0-82.0 μg/L. 
 
 
 
 
 
Time 0 h 8 h 24 h 48 h 72 h 96 h 120 h 144 h 192 h 240 h 288 h 384 h 480 h
Cat 1  fPLI 0.1 17.1 29.3 18.7 13.6 11.8 10.8 8.4 9.0 4.9 3.7 1.4 0.2
Cat 1  fTLI 47 230 168 80 37 55 39 38 24 30 38 24 25
Cat 2  fPLI 1.0 20.1 25.8 17.6 12.7 7.5 5.2 4.6 6.2 6.7 3.0 3.0 2.8
Cat 2  fTLI 57 336 256 37 109 14 15 18 72 81 41 48 34
Cat 3  fPLI 0.8 34.8 50.9 34.5 12.5 4.6 3.7 3.1 2.3 2.2 1.7 2.6 2.5
Cat 3  fTLI 54 1856 5008 159 67 32 18 8 11 5 8 20 19
Cat 4  fPLI 0.1 28.9 25.1 15.9 22.5 17.1 19.5 13.6 2.4
Cat 4  fTLI 94 972 212 50 130 92 164 210 129 54
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Fig rum fPLI and fTLI concentrations for cat 1.  This graph shows the comparison of serum fPLI concentration to 
seru  concentration for cat 1 over time.  The dotted line depicts the upper limit of the normal range for fTLI and fPLI.  
Ser I concentration remains elevated above the upper limit of the control range much longer than serum fTLI 
con n. 
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Figure 8-Serum fPLI and fTLI concentrations for cat 2.  This graph shows the comparison of serum fPLI concentration to 
serum fTLI concentration for cat 2 over time.  The dotted line depicts the upper limit of the normal range for fTLI and fPLI.  
Serum fPLI concentration remains elevated above the upper limit of the control range much longer than serum fTLI 
concentration. 
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F erum fPLI and fTLI concentrations for cat 3.  This line graph shows the comparison of serum fPLI concentration to 
se I concentration for cat 3 over time.  The dotted line depicts the upper limit of the normal range for fTLI and fPLI.  
S LI concentration remains elevated above the upper limit of the control range much longer than serum fTLI 
co tion. 
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Figure 10-Serum fPLI and fTLI concentrations for cat 4.  This graph shows the comparison of serum fPLI concentration to 
serum fTLI concentration for cat 4 over time.  The dotted line depicts the upper limit of the normal range for fTLI and fPLI.  
Serum fPLI concentration remains elevated above the upper limit of the control range much longer than serum fTLI 
concentration.
0
100
200
300
400
500
600
700
800
900
1000
0 h 24 h 72 h 120 h 192 h 288 h 480 h
0
5
10
15
20
25
30
35
fTLI fPLI
 
fTLI 
fPLI 
Serum fPLI and fTLI concentrations for cat 4 
Time (hours) 
  
48 
DISCUSSION 
One can draw two important conclusions from comparison of serum fPLI and 
fTLI concentrations in cat 1 (Fig 7).  The first conclusion is that both serum fPLI and 
fTLI concentrations exhibit the same trend over time.  That is, both parameters increase 
initially and then decrease.  Secondly, and more importantly, serum fPLI concentrations 
remain elevated above the upper limit of the fPLI control range much longer than do 
serum fTLI concentrations.  Serum fTLI concentrations drop back into the normal range 
after approximately 48 hours, while serum fPLI concentrations do not reenter the normal 
range until 288 hours.  This is very important clinically because it prolongs the duration 
of time that a diagnosis of feline pancreatitis can be made and substantially increases the 
sensitivity for serum fPLI when compared to serum fTLI. 
Similar findings can also be observed for cat 2.  Figure 8 shows that the fTLI 
concentration returns back into the normal range after the initial peak after 
approximately 48 hours, whereas the fPLI concentration remains elevated above the 
upper limit of the normal range for approximately 288 hours after the initial peak.  Thus, 
as for cat 1, serum fPLI is much more sensitive for pancreatitis than is serum fTLI 
concentration. 
The concentrations of serum fPLI and fTLI for cat 3 are shown in Figure 9.  The 
same conclusions drawn before are also valid here for cat 3.  The one noted difference in 
the concentrations of serum fPLI and fTLI for cat 3 is that the fTLI concentration 
remains above the normal range until approximately 60 hours (2.5 days), and the fPLI 
concentrations drop below the upper limit of the normal range at approximately 110 
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hours (4.6 days), which is much sooner than any of the other three cats analyzed.  These 
data still show that the fPLI concentration remains elevated above the normal range 
longer than the fTLI value, which is important from a clinical point of view. 
The data shown for cat 4 (Fig 10) also show that as for the previous three cats the 
fTLI concentration drops below the upper limit of the normal range at approximately 48 
hours, while the fPLI concentration remains elevated above the upper limit of the normal 
range for approximately 240 hours, once again indicating a higher sensitivity of the fPLI 
assay for feline pancreatitis. 
In conclusion, serum fPLI concentration is increased in cats with experimentally 
induced pancreatitis.  Also, serum fPLI concentration decreased back into the reference 
range many days after serum fTLI concentration.  This suggests that the measurement of 
serum fPLI concentration is likely to be more sensitive for a diagnosis of feline 
pancreatitis than the measurement of serum fTLI.  These encouraging initial data need to 
be confirmed in cats with spontaneous pancreatitis. 
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CHAPTER V 
CONCLUSIONS 
 
The objective of this project was to test the hypothesis that the measurement of 
serum feline pancreatic lipase immunoreactivity (fPLI) is useful in the diagnosis of 
pancreatitis.  To test this hypothesis, feline classical PL was purified from pancreatic 
tissue, antiserum against this protein was raised and purified, a radioimmunoassay for 
the measurement of fPLI in cat serum was developed and validated, and the assay was 
evaluated in clinically healthy cats and cats with experimentally induced pancreatitis. 
This is the first detailed description of the purification of feline classical PL.  
Feline PL was extracted and purified from feline pancreatic tissue.  Partial 
characterization of feline PL revealed a molecular mass of 52.4 kDa, an approximate 
specific absorbance at 280 nm of 1.18 for a 1 mg/ml solution, a specific lipase activity of 
10,261 U/mg using tributyrin as a substrate, and a N-terminal amino acid sequence for 
the first 25 amino acid residues that showed a very high sequence homology with 
previously reported sequences of classical PL purified in other species (Table 3).19,66,69-71 
Antiserum directed against fPL was raised in New Zealand White rabbits by 
repeated injection of the purified protein emulsified with complete or incomplete 
Freund's adjuvant.  The antibody production was conducted at Lampire Biological 
Laboratories, Inc. (LBL) in Pipersville, PA following their Express-Line PLUS protocol 
using New Zealand White rabbits. 
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A radioimmunoassay (RIA) for the measurement of feline pancreatic lipase 
immunoreactivity (fPLI) in serum was successfully developed and validated.  The assay 
was determined to be sufficiently accurate and precise for clinical use, with a limited 
linearity and reproducibility in the upper and lower areas of the working range.  After 
evaluating samples from 30 clinically healthy cats with the validated RIA the control 
range was established as 1.2 to 3.8 μg/L (Fig 6). 
Serum fPLI concentration was measured in serum collected from an unrelated 
research project involving four cats that were experimentally induced with pancreatitis.  
Cats 1, 2, and 3 had thirteen serum samples taken at specific time points.  Cat 4 had ten 
serum samples taken at specific time points.  All samples were evaluated for serum fPLI 
and fTLI concentrations so that a comparison could be made between the two 
concentrations over time.  The data presented show that serum fPLI concentration 
decreased back into the reference range many days after serum fTLI concentration 
(Table 8, Figs 7 to 10).  This suggests that the measurement of serum fPLI concentration 
is likely to be more sensitive for a diagnosis of feline pancreatitis than the measurement 
of serum fTLI.  The presented data are also promising in regards to the fact that the 
window of diagnosis of feline pancreatitis is much larger when measuring serum fPLI 
(approximately 10 days) versus measuring serum fTLI (approximately 2 days).  Future 
studies need to be conducted with a larger sample size of cats known to have pancreatitis 
in order to systematically evaluate the sensitivity and specificity of serum fPLI 
concentration as measured by radioimmunoassay for the diagnosis of pancreatitis in the 
cat. 
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In summary, feline classical PL was successfully purified, antibodies against fPL 
were produced, and a radioimmunoassay for the measurement of feline pancreatic lipase 
immunoreactivity (fPLI) was developed and validated.  The work completed during this 
project and presented in this thesis supports the hypothesis that serum fPLI concentration 
is useful for the diagnosis of feline pancreatitis. 
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